Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation

This study has been completed.
Sponsor:
Collaborator:
Ironwood Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Forest Laboratories
ClinicalTrials.gov Identifier:
NCT00765882
First received: October 1, 2008
Last updated: December 19, 2012
Last verified: December 2012
  Purpose

The objective of this trial is to determine the efficacy and safety of linaclotide administered to patients with chronic constipation (CC). The primary efficacy parameter is the percentage of patients in each treatment group that meet the protocol definition for Complete Spontaneous Bowel Movement (CSBM) Overall Responder


Condition Intervention Phase
Chronic Constipation
Drug: Linaclotide 290 micrograms
Drug: Linaclotide 145 micrograms
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial of Linaclotide Administered Orally for 12 Weeks in Patients With Chronic Constipation

Resource links provided by NLM:


Further study details as provided by Forest Laboratories:

Primary Outcome Measures:
  • Complete Spontaneous Bowel Movement (CSBM) Overall Responder [ Time Frame: Change from Baseline to Week 12 ] [ Designated as safety issue: No ]

    A 12-week CSBM overall responders was defined as a patient who for at least 9 of the 12 weeks of the treatment period had a CSBM weekly frequency rate that was 3 or greater and increased by 1 or more from baseline.

    A CSBM was defined as a spontaneous bowel movement (SBM) that was associated with a sense of complete evacuation.

    An SBM was defined as a bowel movement (BM) that occurred in the absence of laxative, enema, or suppository use on either the calendar day of the BM or the calendar day before the BM.



Secondary Outcome Measures:
  • 12-week Complete Spontaneous Bowel Movement (CSBM) Frequency Rate [ Time Frame: Change from Baseline to Week 12 ] [ Designated as safety issue: No ]
    The number of CSBMs per week.

  • 12-Week Spontaneous Bowel Movement (SBM) Frequency Rate [ Time Frame: Change from Baseline to Week 12 ] [ Designated as safety issue: No ]
    A patient's 12-week spontaneous bowel movement (SBM) frequency rate was the number of SBMs per week calculated over the 12-weeks of the treatment period.

  • 12-Week Stool Consistency [ Time Frame: Change from Baseline to Week 12 ] [ Designated as safety issue: No ]

    The consistency of each BM was assessed using the 7-point Bristol Stool Form Scale:

    1. = separate hard lumps like nuts [difficult to pass]
    2. = sausage shaped but lumpy
    3. = like a sausage but with cracks on surface
    4. = like a sausage or snake, smooth and soft
    5. = soft blobs with clear-cut edges [passed easily]
    6. = fluffy pieces with ragged edges, a mushy stool
    7. = watery, no solid pieces [entirely liquid]

  • 12-Week Severity of Straining [ Time Frame: Change from Baseline to Week 12 ] [ Designated as safety issue: No ]
    Straining is measured on a 5-point scale, where a value of 1 is "not at all" and a value of 5 is "an extreme amount.

  • 12-Week Abdominal Discomfort [ Time Frame: Change from Baseline to Week 12 ] [ Designated as safety issue: No ]
    Abdominal discomfort is based on a 5-point scale where a value of l is "none" and a value of 5 is "very severe."

  • 12-Week Bloating [ Time Frame: Change from Baseline to Week 12 ] [ Designated as safety issue: No ]
    Bloating was based on a 5-point scale where a value of l is "none" and a value of 5 is "very severe".

  • 12-Week Constipation Severity [ Time Frame: Change from Baseline to Week 12 ] [ Designated as safety issue: No ]
    Constipation severity was based on a 5-point ordinal scale where a value of l is "none" and a value of 5 is "very severe".


Enrollment: 633
Study Start Date: September 2008
Study Completion Date: August 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Linaclotide 290 micrograms
Drug: Linaclotide 290 micrograms
Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
Experimental: 2
Linaclotide 145 micrograms
Drug: Linaclotide 145 micrograms
Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
Placebo Comparator: 3
Matching placebo
Drug: Placebo
Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient has completed a colonoscopy according to the AGA criteria, with no clinically significant findings
  • Patient has successfully completed protocol procedures (with no clinically significant findings): physical exam, 12-lead ECG, or clinical laboratory tests
  • Patient meets protocol criteria for CC: reports < 3 bowel movements per week and reports straining, lumpy or hard stools, and/or sensation of incomplete evacuation during > 25% of BMs
  • Patient demonstrates continued chronic constipation through Pretreatment Period
  • Patient is compliant with IVRS

Exclusion Criteria:

  • Patient has history of loose or watery stools
  • Patient has symptoms of or been diagnosed with Irritable Bowel Syndrome (IBS)
  • Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease or condition that can affect GI motility
  • Patient has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00765882

  Hide Study Locations
Locations
United States, Alabama
Forest Investigative Site
Birmingham, Alabama, United States, 35205
Forest Investigative Site
Birmingham, Alabama, United States, 35215
Forest Investigative Site
Huntsville, Alabama, United States, 35801
United States, Arizona
Forest Investigative Site
Chandler, Arizona, United States, 85225
Forest Investigative Site
Mesa, Arizona, United States, 85210
Forest Investigative Site
Peoria, Arizona, United States, 85381
Forest Investigative Site
Phoenix, Arizona, United States, 85012
Forest Investigative Site
Scottsdale, Arizona, United States, 85251
Forest Investigative Site
Tucson, Arizona, United States, 85741
United States, California
Forest Investigative Site
Burbank, California, United States, 91505
Forest Investigative Site
Encinitas, California, United States, 92024
Forest Investigative Site
Foothill Ranch, California, United States, 92610
Forest Investigative Site
Los Angeles, California, United States, 90036
Forest Investigative Site
Orange, California, United States, 92869
Forest Investigative Site
Westlake Village, California, United States, 91361
United States, Colorado
Forest Investigative Site
Boulder, Colorado, United States, 80304
Forest Investigative Site
Colorado Springs, Colorado, United States, 80909
Forest Investigative Sites
Denver, Colorado, United States, 80205
Forest Investigative Site
Longmont, Colorado, United States, 80501
Forest Investigative Site
Wheat Ridge, Colorado, United States, 80033
United States, Connecticut
Forest Investigative Site
Waterbury, Connecticut, United States, 06708
United States, Florida
Forest Investigative Site
Boca Raton, Florida, United States, 33486
Forest Investigative Site
Bradenton, Florida, United States, 34203
Forest Investigative Site
Brooksville, Florida, United States, 34601
Forest Investigative Site
Ft. Myers, Florida, United States, 33916
Forest Investigative Site
Jupiter, Florida, United States, 33458
Forest Investigative Site
Kissimmee, Florida, United States, 34741
Forest Investigative Site
Miami, Florida, United States, 33143
Forest Investigative Site
Ocala, Florida, United States, 34471
Forest Investigative Site
Orlando, Florida, United States, 32806
Forest Investigative Site
Panama City, Florida, United States, 32405
Forest Investigative Site
Pembroke Pines, Florida, United States, 33024
Forest Investigative Site
St. Petersburg, Florida, United States, 33709
Forest Investigative Site
Tampa, Florida, United States, 33606
Forest Investigative Site
Trinity, Florida, United States, 34655
Forest Investigative Site
Zephyrhills, Florida, United States, 33542
United States, Georgia
Forest Investigative Site
Atlanta, Georgia, United States, 30342
Forest Investigative Site
Marietta, Georgia, United States, 30060
Forest Investigative Site
Marietta, Georgia, United States, 30067
Forest Investigative Site
Stockbridge, Georgia, United States, 30281
Forest Investigative Site
Woodstock, Georgia, United States, 30189
United States, Idaho
Forest Investigative Site
Idaho Falls, Idaho, United States, 83404
United States, Illinois
Forest Investigative Site
Rockford, Illinois, United States, 61107
United States, Indiana
Forest Investigative Site
Elkhart, Indiana, United States, 46514
Forest Investigative Site
Evansville, Indiana, United States, 47714
Forest Investigative Site
Indianapolis, Indiana, United States, 46237
Forest Investigative Site
Indianapolis, Indiana, United States, 46254
United States, Iowa
Forest Investigative Site
Iowa City, Iowa, United States, 52242
United States, Kansas
Forest Investigative Site
Arkansas City, Kansas, United States, 67005
Forest Investigative Site
Newton, Kansas, United States, 67114
Forest Investigative Site
Wichita, Kansas, United States, 67205
Forest Investigative Site
Wichita, Kansas, United States, 67207
United States, Kentucky
Forest Investigative Site
Lexington, Kentucky, United States, 40509
Forest Investigative Site
Madisonville, Kentucky, United States, 42431
United States, Maryland
Forest Investigative Site
Chevy Chase, Maryland, United States, 20815
Forest Investigative Site
Hagerstown, Maryland, United States, 21742
Forest Investigative Site
Lutherville, Maryland, United States, 21093
United States, Massachusetts
Forest Investigative Site
Boston, Massachusetts, United States, 02135
United States, Minnesota
Forest Investigative Site
Chaska, Minnesota, United States, 55318
United States, Missouri
Forest Investigative Site
St. Louis, Missouri, United States, 63128
Forest Investigative Site
St. Louis, Missouri, United States, 63110
United States, New Jersey
Forest Investigative Site
Vineland, New Jersey, United States, 08360
United States, New Mexico
Forest Investigative Site
Albuquerque, New Mexico, United States, 87106
United States, New York
Forest Investigative Site
Brooklyn, New York, United States, 11214
Forest Investigative Site
Great Neck, New York, United States, 11021
Forest Investigative Site
Great Neck, New York, United States, 11023
United States, North Carolina
Forest Investigative Site
Fayetteville, North Carolina, United States, 28304
Forest Investigative Site
Greensboro, North Carolina, United States, 27403
Forest Investigative Site
Hickory, North Carolina, United States, 28601
Forest Investigative Site
Raleigh, North Carolina, United States, 27612
Forest Investigative Site
Wilmington, North Carolina, United States, 28401
Forest Investigative Site
Winston-Salem, North Carolina, United States, 27103
United States, North Dakota
Forest Investigative Site
Bismark, North Dakota, United States, 58501
United States, Ohio
Forest Investigative Site
Akron, Ohio, United States, 44302
Forest Investigative Site
Cincinnati, Ohio, United States, 45219
Forest Investigative Site
Cleveland, Ohio, United States, 44122
United States, Oklahoma
Forest Investigative Site
Oklahoma City, Oklahoma, United States, 73104
Forest Investigative Site
Tulsa, Oklahoma, United States, 74135
United States, Pennsylvania
Forest Investigative Site
Bensalem, Pennsylvania, United States, 19020
Forest Investigative Site
Pittsburgh, Pennsylvania, United States, 15206
United States, South Carolina
Forest Investigative Site
Greenville, South Carolina, United States, 29615
Forest Investigative Site
Greer, South Carolina, United States, 29651
United States, Tennessee
Forest Investigative Site
Nashville, Tennessee, United States, 37205
United States, Texas
Forest Investigative Site
Austin, Texas, United States, 78705
Forest Investigative Site
Dallas, Texas, United States, 75234
Forest Investigative Site
Houston, Texas, United States, 77090
Forest Investigative Site
Lake Jackson, Texas, United States, 77566
Forest Investigative Site
San Antonio, Texas, United States, 78229
Forest Investigative Site
San Antonio, Texas, United States, 78209
United States, Utah
Forest Investigative Site
Salt Lake City, Utah, United States, 84102
United States, Virginia
Forest Investigative Site
Charlottesville, Virginia, United States, 22911
Forest Investigative Site
Christianburg, Virginia, United States, 24073
Forest Investigative Site
Newport News, Virginia, United States, 23606
Forest Investigative Site
Norfolk, Virginia, United States, 23502
Forest Investigative Site
Norfolk, Virginia, United States, 23507
Forest Investigative Site
Richmond, Virginia, United States, 23294
United States, Washington
Forest Investigative Site
Bellevue, Washington, United States, 98402
Forest Investigative Site
Lakewood, Washington, United States, 98499
Forest Investigative Site
Wenatchee, Washington, United States, 98801
United States, Wisconsin
Forest Investigative Site
Milwaukee, Wisconsin, United States, 53209
Canada, British Columbia
Forest Investigative Site
Vancouver, British Columbia, Canada, V67 2K5
Canada, Ontario
Forest Investigative Site
Hamilton, Ontario, Canada, L8N 4A6
Forest Investigative Site
Newmarket, Ontario, Canada, L3Y 7V1
Forest Investigative Site
Ottawa, Ontario, Canada, K2c 3R2
Forest Investigative Site 2
Sarnia, Ontario, Canada, N7T 4X3
Forest Investigative Site 1
Sarnia, Ontario, Canada, N7T 4X3
Forest Investigative Site
Sudbury, Ontario, Canada, P3E 1H5
Forest Investigative Site
Toronto, Ontario, Canada, MCN 2V7
Sponsors and Collaborators
Forest Laboratories
Ironwood Pharmaceuticals, Inc.
Investigators
Study Director: Paul F.C. Eng, PhD Forest Laboratories
  More Information

No publications provided by Forest Laboratories

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Forest Laboratories
ClinicalTrials.gov Identifier: NCT00765882     History of Changes
Other Study ID Numbers: LIN-MD-01
Study First Received: October 1, 2008
Results First Received: September 28, 2012
Last Updated: December 19, 2012
Health Authority: United States: Food and Drug Administration
Canada: Health Canada

Keywords provided by Forest Laboratories:
Constipation
Chronic Constipation
Linaclotide

Additional relevant MeSH terms:
Constipation
Signs and Symptoms, Digestive
Signs and Symptoms

ClinicalTrials.gov processed this record on October 16, 2014